Exagen Reports Record Q1 2026 Revenue, Unveils Strategic Growth Plans
Exagen Inc delivered record Q1 2026 revenue, marking its highest quarterly sales to date, driven by increased adoption of its autoimmune diagnostics portfolio. Management outlined strategic growth plans including expanded commercial partnerships and advancement of its proprietary testing pipeline.
1. Q1 2026 Earnings Highlights
Exagen posted record quarterly revenue in Q1 2026, achieving its highest sales ever thanks to stronger demand for its autoimmune diagnostics products. Volume gains across core assays contributed to a significant year-over-year increase in overall revenue.
2. Strategic Growth Outlook
Leadership detailed plans to expand commercial partnerships across North America and Europe to broaden market access. The company also emphasized acceleration of its proprietary testing pipeline, targeting new indications in systemic lupus and related autoimmune conditions.